Navigation Links
Hospira Supports Newly Introduced Biogenerics Legislation
Date:3/11/2009

-- Urges Quick Passage By Congress --

LAKE FOREST, Ill., March 11 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, announced today its enthusiastic support for the biogenerics bill co-sponsored by House Energy and Commerce Committee Chairman Henry Waxman, D-Calif., and Rep. Nathan Deal, R-Ga., and urges quick passage by Waxman's committee and the full Congress.

"The approval of biogenerics legislation would provide Americans access to more affordable biologic drugs and save the healthcare system billions of dollars," said Christopher Begley, chairman and chief executive officer, Hospira. "We look forward to working with Congress and the Obama administration to pass biogenerics legislation in 2009."

The Senate is expected to introduce similar legislation soon.

Although biogeneric drugs - generic versions of currently marketed biopharmaceuticals - are widely available in Europe and other parts of the world, they are not sold in the United States. The bipartisan bill introduced Wednesday, titled the "Promoting Innovation and Access to Life-Saving Medicine Act," would create a legislative pathway allowing the U.S. Food and Drug Administration (FDA) to approve safe and effective biogenerics to compete with existing biologic drugs, some of which currently cost more than $100,000 a year per patient. In Europe, biogeneric drugs have been shown to lower costs by around 20 percent.

The new legislation, like the original 1984 Hatch-Waxman legislation that provided access to safe and affordable generic drugs, would allow innovator companies - those that originally introduced biologic drugs - a five-year data exclusivity period for their products during which generic companies would not compete. Five years of exclusivity protects innovator companies' original investments in their products, and also enables relatively quick access to affordable generic substitutions.

Estimates for savings from biogeneric drugs range from $12 billion over 10 years by the Congressional Budget Office (CBO)(1), which assumed a 12-year exclusivity period and focused on savings to the U.S. government alone, to $378 billion over 20 years(2) from noted economist Robert J. Shapiro, who looked at potential savings to U.S. society in general.

Hospira is the only U.S. company selling a biogeneric drug in Europe today. Hospira's Retacrit(R) (epoetin zeta), a treatment for anemia associated with chronic kidney failure and chemotherapy-induced anemia, is available in more than a dozen European countries.

        (1) FDA Week, "CBO Nearly Doubles Estimated Savings From Generic
            Biologics;" Dec. 26, 2008
        (2) Insmed, Inc., "Study By Leading Economist Identifies Potential for
            $378 Billion of Savings From Follow On Biologics;" Feb. 11, 2008

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hospira Advances Patient Safety With New GemStar(R) SP Infusion System
2. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
3. Hospira Hosts Conference Call for Third-Quarter 2008 Earnings
4. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
5. Hospira Expands Board of Directors
6. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
7. Biogenerics Will Save Billions, Says Hospira CEO
8. Charlotte Anti-Aging Expo & Symposium Supports Free Clinics
9. BioIQ Supports American Heart Month to Raise Awareness About Heart Disease, the #1 Killer of Women
10. Nonprofit Puts the Power to Cure Neurological Disease in the Hands of the Masses: Texting Technology Brings Awareness & Supports Research
11. Best Practice Database Supports Bio-Pharma Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... Pa. , April 26, 2017  Genisphere ... delivery platform, has signed a collaborative and sponsored ... Dr. Silvia Muro . The overall goal ... and pharmacodynamics of various 3DNA designs and formulations ... involve targeting diseases of the vasculature as well ...
(Date:4/25/2017)... CA (PRWEB) , ... April 25, 2017 , ... ... of L3 Healthcare, is pleased to announce the company is now a certified ... The iMedNet software certification enables the company’s clinical research team to build, ...
(Date:4/25/2017)... Gatos, California (PRWEB) , ... April 25, 2017 ... ... business, Analytical Services and Metrology Partners.     , Covalent’s Analytical Services unit ... Most samples can be measured within 24 hours of receipt. There are no ...
(Date:4/24/2017)... 2017  Dante Labs announced today the offer of whole ... $900). While American individuals have been able to access WGS ... access WGS below EUR 1,000. The sequencing includes ... information to make informed decisions about disease monitoring, prevention, nutrition, ... ...
Breaking Biology Technology:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):